Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print T cell-based HIV vaccine candidate demonstrates positive results

T cell-based HIV vaccine candidate demonstrates positive results

November 10, 2008

Study demonstrates proof-of-concept for vaccine model

BOSTON -- The question of whether or not to continue to pursue the development of T-cell-based HIV-1 vaccines has been a source of controversy following last year's widely publicized failure of the field's most promising candidate, a vaccine developed by Merck known as V520.




Now a study led by investigators at Beth Israel Deaconess Medical Center (BIDMC) provides the proof-of-concept that a T-cell-based strategy remains a viable course to follow.

Described in today's dvance On-line Publication of Nature, the study showed that an improved regimen using two distinct adenovirus vectors - rAd26 prime/rAd5 boost - and expressing the simian immunodeficiency virus (SIV) Gag protein, resulted in potent T-cell immune responses leading to long-term immune control of an SIV challenge in monkeys. The findings demonstrate for the first time using this stringent animal model that such a vaccine may be effective in the fight against AIDS.

"This is a controversial field right now," says the study's lead scientist Dan Barouch, MD, PhD, Principal Investigator of the NIH-sponsored Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) program, who is working to develop new HIV-1 vaccine candidates. "Despite the disappointing setbacks in HIV-1 vaccine development this past year, our findings suggest that we're not at the end of the road when it comes to T-cell vaccines. Our data show that T-cell vaccines that elicit greater magnitude, breadth, and quality of immune responses as compared with the Merck vaccine can result in improved protection in the rhesus monkey model of AIDS."

The induction of the immune system's "killer" T-cells as a means of protecting against HIV-1 is designed to overcome a number of unique obstacles that make the virus impervious to traditional vaccine strategies, which typically work by producing antibodies to eliminate the invading virus. Instead, T-cell generated immunity works by selectively targeting and destroying any cells that have already been infected by the virus.

"Although our vaccine regimen did not prevent acquisition of SIV infection, it substantially reduced the levels of virus in the blood of these animals and prevented the development of AIDS," says Barouch, who is also an Associate Professor of Medicine at Harvard Medical School.

Barouch and his colleagues in the Division of Viral Pathogenesis at BIDMC, in collaboration with the biotechnology company Crucell Holland BV, have spent the past three years developing new rare serotype adenoviral vectors, which deliver HIV antigens and are the basis for one strategy of HIV-1 vaccine development. Viral vector vaccines are made by deleting one or more genes from a harmless or attenuated virus, in this case, adenovirus. Segments of DNA-encoding HIV-1 proteins are inserted in place of the deleted genes and thereby transfer the proteins into human cells to stimulate an immune response to the HIV-1 virus.

Last year's Merck trial used as its vector adenovirus serotype 5 (rAd5) which is a virus responsible for the common cold. "Because Ad5 is encountered frequently in the environment," explains Barouch, "many individuals harbor preexisting immunity to this virus." As a result, following vaccination, this vector often proves ineffective in delivering its "cargo" to induce an immune response to HIV.

In the new study, Barouch's laboratory used an rAd26 viral vector as its means of transport. Ad26 is rarely encountered in the human population and has the ability to induce a potent immune response, providing protective efficacy against SIV.

Also distinct from the Merck study, the authors made use of a heterologous "prime-boost" system to enhance the vaccine's immunogenicity. "In most cases, the immune response induced by a single dose of a vaccine isn't strong enough or sustainable enough to provide effective protection," explains Barouch. By administering a second "boost" the antigen's immune response can be enhanced. In this case, the scientists successively administered the same antigen in two separate vectors: The first rAd26 vector "primed" the animals' immune responses; re-exposure to the same antigen in a second rAd5 vector provided the "boost."

Their results showed that when challenged with a lethal dose of SIV, the vaccinated animals were able to reduce viral replication and to remain healthy for more than 500 days following infection, indicating that the vaccine had sparked a powerful immune response.

"This is an extremely important study because it shows that there is still hope for vaccines currently in the pipeline," says Bruce Walker, MD, Director of the Harvard University Center for AIDS Research (CFAR). "It also gives the first clear indication of the level and type of immunity that will likely be needed for an AIDS vaccine to work."

More than 25 years after the discovery of HIV-1, AIDS remains one of the world's most devastating health problems. An estimated 33.2 million people currently live with HIV/AIDS while 2.5 million new infections were reported in 2007 alone.

Beth Israel Deaconess Medical Center



Related Immune Response Current Events and Immune Response News Articles Immune Response Current Events and Immune Response News RSS Immune Response Current Events and Immune Response News RSS
New Notre Dame study provides insights into the molecular basis of tumor cell behavior
A new study by a team of researchers led by Crislyn D'Souza-Schorey, associate professor of biological sciences at the University of Notre Dame, sheds light on the molecular basis by which tumor cells modulate their surroundings to favor cancer progression.

New Synthetic Molecules Trigger Immune Response to HIV and Prostate Cancer
Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases.

Common Pain Relievers May Dilute Power of Flu Shots
With flu vaccination season in full swing, research from the University of Rochester Medical Center cautions that use of many common pain killers - Advil, Tylenol, aspirin - at the time of injection may blunt the effect of the shot and have a negative effect on the immune system.

PATH Malaria Vaccine Initiative shares strategy for developing 'next-generation' malaria vaccines
Marking its tenth anniversary year, the PATH Malaria Vaccine Initiative (MVI) today unveiled a new strategy that sets the stage for an aggressive push targeting the long-term goal of eliminating and eradicating malaria. Malaria is one of the world's deadliest infectious diseases, killing nearly 900,000 people a year, most of them children in sub-Saharan Africa.

Study reveals a 'missing link' in immune response to disease
The immune system's T cells have the unique responsibilities of being both jury and executioner. They examine other cells for signs of disease, including cancers or infections, and, if such evidence is found, rid them from the body. Precisely how T cells shift so swiftly from one role to another, however, has been a mystery.

Initial Results Show Pregnant Women Mount Strong Immune Response To One Dose of 2009 H1N1 Flu Vaccine
Healthy pregnant women mount a robust immune response following just one dose of 2009 H1N1 influenza vaccine, according to initial results from an ongoing clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.

Progress made on group B streptococcus vaccine
Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have completed a Phase II clinical study that indicates a vaccine to prevent Group B Streptococcus (GBS) infection is possible.

Bacteria 'launch a shield' to resist attack
Researchers from the University of Copenhagen and the Technical University of Denmark along with other collaborators in Denmark and the US found that the bacterium Pseudomonas aeruginosa can 'switch on' production of molecules that kill white blood cells - preventing the bacteria being eliminated by the body's immune system.

Scientists use world's fastest supercomputer to create the largest HIV evolutionary tree
Supporting Los Alamos National Laboratory's role in the international Center for HIV/AIDS Vaccine Immunology (CHAVI) consortium, researchers are using the Roadrunner supercomputer to analyze vast quantities of genetic sequences from HIV infected people in the hope of zeroing in on possible vaccine target areas.

Study shows how carbon nanotubes can affect lining of the lungs
Carbon nanotubes are being considered for use in everything from sports equipment to medical applications, but a great deal remains unknown about whether these materials cause respiratory or other health problems.
More Immune Response Current Events and Immune Response News Articles
Immune Response and the Eye (Chemical Immunology)

Immune Response and the Eye (Chemical Immunology)
by Jerry Y. Niederkorn (Editor), Henry J. Kaplan (Editor)

In memory of J. Wayne Streilein, the pioneer in ocular immunology The second edition of Immune >Response and the Eye' highlights recent insights into the >dangerous compromise' between the immune system and the eye, which protects the eye against pathogens while limiting inflammation and immune-mediated injury to ocular tissues with little or no regenerative potential. It discusses the broad spectrum of physiological, immunological, anatomical, and biochemical adaptations that conspire to closely regulate the tone and tenor of immune responses in the eye. This volume further describes immune-mediated diseases that occur when the compromise between the immune system and the eye is breached. This breakdown in immune privilege threatens the vision of millions each year. Finally, recent...

Understanding Hereditary Angioedema: A Mysterious Out-of-Control Immune Response

Understanding Hereditary Angioedema: A Mysterious Out-of-Control Immune Response

Part of the award winning public television series Healthy Body/Healthy Mind. Its called Hereditary Angioedema and its so rare popular television shows have used it as one of their mystery diagnoses. But for the people who suffer with this condition the drama associated with an episode of hereditary angioedema is anything but entertaining. It can be harrowing and horrifying because a person's face or knees or other parts of the body that once looked normal suddenly takes on grotesque proportions due to an unusual amount of swelling. This condition baffled scientists and researchers for many years but today there are new treatments for hereditary angioedema that are helping people with this condition live healthy normal lives. In this program we'll hear what the experts have discovered...

Antioxidant + Resveratrol , (60 Capltes/bottle) This product provides nutritional support to defend against the effects of free radicals. Resveratrol is a type of polyphenol called a phytoalexin. Resvertraol works by binding to a class of proteins called sirtuins, which regulate the enzymes that can stimulate cancer-cell growth and suppress immune response. Resveratrol may also have powerful and diverse effects on the heart and blood vessels.

Antioxidant + Resveratrol , (60 Capltes/bottle) This product provides nutritional support to defend against the effects of free radicals. Resveratrol is a type of polyphenol called a phytoalexin. Resvertraol works by binding to a class of proteins called sirtuins, which regulate the enzymes that can stimulate cancer-cell growth and suppress immune response. Resveratrol may also have powerful and diverse effects on the heart and blood vessels.
by Vitamore

Free-radicals (also called oxidants) are highly unstable molecules that can damage cell membranes. This may start a process that leads to several chronic diseases and may be involved with many aspects of aging. Free radicals are produced in the body during normal cell metabolism, and may also be caused by other environmental and lifestyle factors such as stress, smoking, polution, etc. This product provides nutritional support to defend against the effects of free radicals using the antioxidant vitamins of C and E and the trace elements of Zinc and Selenium. The key ingredient is the flavonoid-rich Resveratrol. Resveratrol is a type of polyphenol called a phytoalexin. Resvertraol works by binding to a class of proteins called sirtuins, which regulate the enzymes that can stimulate...

Source Naturals Nk-3 Immune Capsules, With Vitamin C, 250mg, 30-Count Bottle

Source Naturals Nk-3 Immune Capsules, With Vitamin C, 250mg, 30-Count Bottle
by Source Naturals

NK-3 IMMUNE with vitamin C supports numerous natural immune processes, activating the work of macrophages, T cells, B cells, and natural killer or NK cells, the body¿s ¿first line of defense.¿ It stimulates the production of the chemical messengers that activate the body¿s natural immune response and it also supports a healthy circulatory system.

  Understanding Hereditary Angioedema: A Mysterious Out-Of-Control Immune Response
Directed By: Information Television Network



Vetri-DMG Tablets for Dogs & Cats (90 Tabs)

Vetri-DMG Tablets for Dogs & Cats (90 Tabs)
by vetri science

Vetri-DMG Tablets for Dogs & Cats (90 Tabs) (Supports Performance and Immune System Function) Vetri DMG is recommended to help support proper immune response, cardiovascular and skin health, glucose metabolism and proper nerve and brain functions.

The Human Body: How We Fail, How We Heal - DVD - The Teaching Company

The Human Body: How We Fail, How We Heal - DVD - The Teaching Company
by The Teaching Company

Your body is a fortress under constant assault. Infectious diseases, parasites, environmental toxins, physical trauma, allergens, and natural disasters are some external enemies it faces. From the inside, it is threatened by occasional overzealous allergic, immune, and inflammatory responses, as well as by the cellular mutations that produce cancer. Fortunately, the body's defenses are remarkably successful, and most of the time we are unaware of the intense drama taking place within our cells and organs. The intriguing details of this drama make up the field of pathophysiologythe study of the disruptions in a normal body's functions that are caused by disease or injury. Medical students get an exhaustive introduction to this subject early in their training, and the best clinicians are...

Metabolic Maintenance L-Glutamine 500 mg 100 caps

Metabolic Maintenance L-Glutamine 500 mg 100 caps
by Metabolic Maintenance

L-Glutamine 500 mg 100 caps

Bedside Emergencies: Anaphylactic Shock (Volume 3)

Bedside Emergencies: Anaphylactic Shock (Volume 3)
Also With: Concept Media (Primary Contributor)

Describes the body's normal immune response and how it responds physiologically to allergens. Differentiates between anaphylactic and anaphylactoid reactions, describing signs and symptoms. Describes initial interventions to slow down or prevent reaction from becoming life-threatening, as well as more aggressive therapy for severe, progressive reactions.

Cellular Signaling and Innate Immune Responses to RNA Virus Infections

Cellular Signaling and Innate Immune Responses to RNA Virus Infections
by Allan R. Brasier (Editor), Adolfo García-Sastre (Editor)

Infections with RNA viruses represent a significant cause of morbidity and mortality in vertebrates. This volume is written with the belief that a careful examination of the early host responses to these RNA virus infections, as well as of the mechanisms adopted by these viruses to evade early host antiviral responses, will provide a platform of knowledge on which we will be able to develop new and more effective methods for controlling the spread of RNA viruses or modifying their disease course.

© 2009 BrightSurf.com